This new study published in Genes & Diseases by researchers from Emory University and Joseph Maxwell Cleland, Atlanta VA Medical Center provides a comprehensive comparative analysis demonstrating that the chondrogenic potential of mesenchymal progenitors is predicted by their transcriptomic signatures and gene regulatory networks.

Using iMSCs derived from chondrocyte-specific iPSCs and benchmarking them against bone marrow–derived MSCs (BM-MSCs), adipose-derived stem cells (ADSCs), and dedifferentiated chondrocytes, the researchers performed high-density pellet chondrogenesis assays under transient and continuous TGFβ3 stimulation. While adult MSCs displayed robust induction of classical chondrogenic markers, they also exhibited increased hypertrophic gene expression. In contrast, iMSCs generated hyaline-like cartilage with minimal hypertrophic differentiation, notably lacking expression of COL10A1 and ALPL, key markers of terminal chondrocyte maturation.

Mechanistic analyses revealed fundamental differences in TGFβ signaling responses. In adult MSCs, TGFβ3 activated both SMAD2/3 and SMAD1/5 pathways, the latter being associated with hypertrophic progression. Conversely, iMSCs preferentially activated SMAD2/3 without inducing SMAD1/5, providing a molecular explanation for their resistance to hypertrophy. Gene regulatory network analysis further identified unique hub genes governing iMSC chondrogenesis, including EGF, FGFRs, FLT1, and HIF1A, highlighting distinct transcriptional control compared with adult MSC populations.

Bulk RNA sequencing of uncommitted progenitor states uncovered extensive transcriptomic heterogeneity among iMSCs, BM-MSCs, ADSCs, and dedifferentiated chondrocytes. Principal component and clustering analyses segregated each population into distinct molecular clusters, demonstrating that cell source fundamentally shapes progenitor identity. Pathway enrichment analyses revealed that iMSCs possess unique extracellular matrix remodeling and cytokine signaling profiles, suggesting functional differences in immune modulation and tissue repair capacity.

Importantly, integrated transcriptomic and proteomic analyses refined the molecular characterization of MSCs by identifying eight previously unreported non-classical CD surface markers enriched across MSC populations. These markers may enhance MSC stratification beyond current ISCT criteria and potentially predict lineage-specific differentiation capacity.

Together, this study establishes that origin-specific transcriptomic landscapes define the chondrogenic behavior of mesenchymal progenitors. By linking gene regulatory architecture to functional cartilage outcomes, the findings position iMSCs as a promising, scalable source for regenerative cartilage therapies and provide molecular tools to enhance the precision and reproducibility of MSC-based clinical applications.

Reference

Title of Original Paper: Chondrogenic potential of mesenchymal progenitors from somatic and cartilage-derived iPSCs is predicted by their transcriptomic signatures

Journal: Genes & Diseases
Genes & Diseases is a journal for molecular and translational medicine. The journal primarily focuses on publishing investigations on the molecular bases and experimental therapeutics of human diseases. Publication formats include full length research article, review article, short communication, correspondence, perspectives, commentary, views on news, and research watch.

DOI: https://doi.org/10.1016/j.gendis.2025.101730

Funding Information:

• Veteran Affairs CaReAP Award (USA) (No. I01-BX004878)
• Veteran Affairs Merit Award (USA) (No. I01-BX004708)
• Veteran Affairs CReATE Motion Award (USA) (No. I50-RX004845)

# # # # # #
Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus Cite Score: 8.4
Impact Factor: 9.4
# # # # # #

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/
Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/
All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases).
Submissions to Genes & Diseases may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx).

Print ISSN: 2352-4820
eISSN: 2352-3042
CN: 50-1221/R

Contact Us: editor@genesndiseases.cn
X (formerly twitter): @GenesNDiseases (https://x.com/GenesNDiseases)

# # # # # #